线粒体信号通路及其在抗癌药物耐药性中的作用
Ashwani Sharma1, Tarun Virmani2, Girish Kumar2
1Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India.
线粒体是癌症进展和耐药性的关键信号中心. 准线粒体动力学,新陈代谢和亡提供了新的策略来克服抵抗力并改善癌症治疗结果.
科学领域:
- 线粒体生物学和癌症研究.
背景情况:
- 线粒体被认为是影响癌症进展和药物耐药性的关键信号中心.
- 关键因素包括亡信号,DNA突变,线粒体动态和新陈代谢.
研究的目的:
- 审查线粒体在癌症抗药性中的多方面的作用.
- 探索针对性治疗策略,重点关注线粒体功能.
主要方法:
- 关于线粒体在癌症中的作用研究的文献综述.
- 针对线粒体动态和新陈代谢的治疗方法的分析.
- 讨论新的药物输送和重新定位策略.
主要成果:
- 线粒体动力学 (线粒体,融合,裂变) 和新陈代谢对抗性至关重要.
- 向代谢酶 (例如GLUT1,HKII) 和途径 (例如谷氨酸代谢) 可以克服耐药性.
- 结合和基于纳米粒子的方法显示出有希望的结果.
结论:
- 线粒体为克服癌症药物耐药性的可行治疗标.
- 需要进一步的研究和临床转化,以利用线粒体向疗法.
- 包含线粒体策略的个性化治疗计划可以改善患者的治疗结果.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:49Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
